Global Rare Disease Diagnostics Market Size, Top Share, Opportunities, Forecast 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Rare Disease Diagnostics Market Size Analysis

Global Rare Disease Diagnostics Market Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Kits and Assays
  1. By Value
3. Panels
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Gastroenterology Disease
  1. By Value
3. Endocrine and Metabolism Disorders Disease
  1. By Value
4. Cardiovascular Disorders
  1. By Value
5. Neurology Disease
  1. By Value
6. Hematology and Oncology Disease
  1. By Value
7. Dermatology Disease
  1. By Value
8. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. Whole Exome Sequencing
  1. By Value
5. Microarrays
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Diagnostics Laboratories
  1. By Value
4. Research Laboratories & CROs
  1. By Value

North America Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Kits and Assays
  1. By Value
3. Panels
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Gastroenterology Disease
  1. By Value
3. Endocrine and Metabolism Disorders Disease
  1. By Value
4. Cardiovascular Disorders
  1. By Value
5. Neurology Disease
  1. By Value
6. Hematology and Oncology Disease
  1. By Value
7. Dermatology Disease
  1. By Value
8. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. Whole Exome Sequencing
  1. By Value
5. Microarrays
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Diagnostics Laboratories
  1. By Value
4. Research Laboratories & CROs
  1. By Value
U.S.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Kits and Assays
    1. By Value
  3. Panels
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Gastroenterology Disease
    1. By Value
  3. Endocrine and Metabolism Disorders Disease
    1. By Value
  4. Cardiovascular Disorders
    1. By Value
  5. Neurology Disease
    1. By Value
  6. Hematology and Oncology Disease
    1. By Value
  7. Dermatology Disease
    1. By Value
  8. Others
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. Whole Exome Sequencing
    1. By Value
  5. Microarrays
    1. By Value
  6. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Diagnostics Laboratories
    1. By Value
  4. Research Laboratories & CROs
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Kits and Assays
  1. By Value
3. Panels
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Gastroenterology Disease
  1. By Value
3. Endocrine and Metabolism Disorders Disease
  1. By Value
4. Cardiovascular Disorders
  1. By Value
5. Neurology Disease
  1. By Value
6. Hematology and Oncology Disease
  1. By Value
7. Dermatology Disease
  1. By Value
8. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. Whole Exome Sequencing
  1. By Value
5. Microarrays
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Diagnostics Laboratories
  1. By Value
4. Research Laboratories & CROs
  1. By Value
U.K.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Kits and Assays
    1. By Value
  3. Panels
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Gastroenterology Disease
    1. By Value
  3. Endocrine and Metabolism Disorders Disease
    1. By Value
  4. Cardiovascular Disorders
    1. By Value
  5. Neurology Disease
    1. By Value
  6. Hematology and Oncology Disease
    1. By Value
  7. Dermatology Disease
    1. By Value
  8. Others
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. Whole Exome Sequencing
    1. By Value
  5. Microarrays
    1. By Value
  6. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Diagnostics Laboratories
    1. By Value
  4. Research Laboratories & CROs
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Kits and Assays
  1. By Value
3. Panels
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Gastroenterology Disease
  1. By Value
3. Endocrine and Metabolism Disorders Disease
  1. By Value
4. Cardiovascular Disorders
  1. By Value
5. Neurology Disease
  1. By Value
6. Hematology and Oncology Disease
  1. By Value
7. Dermatology Disease
  1. By Value
8. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. Whole Exome Sequencing
  1. By Value
5. Microarrays
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Diagnostics Laboratories
  1. By Value
4. Research Laboratories & CROs
  1. By Value
China
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Kits and Assays
    1. By Value
  3. Panels
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Gastroenterology Disease
    1. By Value
  3. Endocrine and Metabolism Disorders Disease
    1. By Value
  4. Cardiovascular Disorders
    1. By Value
  5. Neurology Disease
    1. By Value
  6. Hematology and Oncology Disease
    1. By Value
  7. Dermatology Disease
    1. By Value
  8. Others
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. Whole Exome Sequencing
    1. By Value
  5. Microarrays
    1. By Value
  6. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Diagnostics Laboratories
    1. By Value
  4. Research Laboratories & CROs
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Kits and Assays
  1. By Value
3. Panels
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Gastroenterology Disease
  1. By Value
3. Endocrine and Metabolism Disorders Disease
  1. By Value
4. Cardiovascular Disorders
  1. By Value
5. Neurology Disease
  1. By Value
6. Hematology and Oncology Disease
  1. By Value
7. Dermatology Disease
  1. By Value
8. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. Whole Exome Sequencing
  1. By Value
5. Microarrays
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Diagnostics Laboratories
  1. By Value
4. Research Laboratories & CROs
  1. By Value
UAE
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Kits and Assays
    1. By Value
  3. Panels
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Gastroenterology Disease
    1. By Value
  3. Endocrine and Metabolism Disorders Disease
    1. By Value
  4. Cardiovascular Disorders
    1. By Value
  5. Neurology Disease
    1. By Value
  6. Hematology and Oncology Disease
    1. By Value
  7. Dermatology Disease
    1. By Value
  8. Others
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. Whole Exome Sequencing
    1. By Value
  5. Microarrays
    1. By Value
  6. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Diagnostics Laboratories
    1. By Value
  4. Research Laboratories & CROs
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Kits and Assays
  1. By Value
3. Panels
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Gastroenterology Disease
  1. By Value
3. Endocrine and Metabolism Disorders Disease
  1. By Value
4. Cardiovascular Disorders
  1. By Value
5. Neurology Disease
  1. By Value
6. Hematology and Oncology Disease
  1. By Value
7. Dermatology Disease
  1. By Value
8. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. Whole Exome Sequencing
  1. By Value
5. Microarrays
  1. By Value
6. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals & Clinics
  1. By Value
3. Diagnostics Laboratories
  1. By Value
4. Research Laboratories & CROs
  1. By Value
Brazil
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Kits and Assays
    1. By Value
  3. Panels
    1. By Value
2. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Gastroenterology Disease
    1. By Value
  3. Endocrine and Metabolism Disorders Disease
    1. By Value
  4. Cardiovascular Disorders
    1. By Value
  5. Neurology Disease
    1. By Value
  6. Hematology and Oncology Disease
    1. By Value
  7. Dermatology Disease
    1. By Value
  8. Others
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. Whole Exome Sequencing
    1. By Value
  5. Microarrays
    1. By Value
  6. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Diagnostics Laboratories
    1. By Value
  4. Research Laboratories & CROs
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Rare Disease Diagnostics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

23andMe Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
3billion Inc.
Agilent Technologies Inc.
Beijing Genomics Institute (BGI)
CENTOGENE N.V.
Eurofins Scientific SE
GENEWIZ Inc.
Illumina Inc.
In-Depth Genomics
Invitae Corporation
Laboratory Corporation of America Holdings
OPKO Health
PerkinElmer Inc.
Quest Diagnostics Incorporated
Travere Therapeutics Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment